Panbela Therapeutics Inc.

141 articles about Panbela Therapeutics Inc.

• Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

  10/25/2023

  Panbela Therapeutics, Inc today announced that an abstract about SBP-101 and CPP-1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) meeting site in the November supplemental issue of the journal Blood.

• Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

  10/24/2023

  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.

• Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101Patent developed in collaboration with Syngene International Ltd.

  9/26/2023

  Panbela today announced an Issue Notification for the Chinese patent 201980010826.7 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

• Panbela to Present at the LD Micro Investor Conference

  9/19/2023

  Panbela Therapeutics, Inc.  announced today that management will be presenting at the LD Micro Conference on Wednesday, October 4, 2023, at 3:30pm PT.

• Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of FlynpoviPatent developed in collaboration with Sanofi

  9/5/2023

  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notification for the Chilean patent 1157-2018 titled “Eflornithine and Sulindac, Fixed Dose Combination Formulation”.

• Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

  8/28/2023

  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.

• Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101

  8/14/2023

  Panbela Therapeutics, Inc. today announced an Issue Notification for the European patent 2019213664 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

• Panbela Provides Business Update and Reports Q2 2023 Financial Results

  8/10/2023

  Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, provides a business update and reports financial results for the quarter ended June 30, 2023.

• Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023

  7/31/2023

  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023.

• Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively EnrollingInterim Data Analysis anticipated in Early 2024

  7/24/2023

  Panbela Therapeutics, Inc. announced it has opened enrollment in the UK and Germany for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.

• Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds

  7/19/2023

  Panbela Therapeutics, Inc. today announced it has divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds ® 1 (USWM), a Kentucky-based specialty pharmaceutical company.

• Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101

  7/17/2023

  Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced an Issue Notification for the Australian patent 2019213664 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

• Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

  7/10/2023

  Panbela Therapeutics, Inc. announces that the independent Data Safety Monitoring Board of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients in the trial.

• Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

  6/28/2023

  Panbela Therapeutics, Inc today announced the SWOG Cancer Research Network’s PACES S0820 Phase III trial passed a single planned futility analysis and will continue.

• Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes

  6/26/2023

  Panbela Therapeutics, Inc announces a poster presentation highlighting the results for CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes at the Endocrine Society meeting, which was held June 15-18, 2023.

• Panbela Announces Closing of Approximately $8.5 Million Public Offering

  6/21/2023

  Panbela Therapeutics, Inc. announced the closing of its previously announced public offering of 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants.

• Panbela Announces Pricing of Approximately $8.5 Million Public Offering

  6/16/2023

  Panbela Therapeutics, Inc. announced the pricing of a public offering of 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at a purchase price of $3.75 per share and associated Public Warrants.

• Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy

  6/13/2023

  Panbela Therapeutics, Inc . (Nasdaq: PBLA) today announced it has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor therapies in combination with CAR-T cell therapies in preclinical models.

• Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes

  6/1/2023

  Panbela Therapeutics, Inc announces a poster presentation highlighting the results for CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes at the Immunology of Diabetes Society (IDS) meeting, which was held May 23-27, 2023.

• Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023

  5/31/2023

  Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that it will implement the previously announced and stockholder approved 1-for-30 reverse split of its common stock.